One of the top cases of the current Supreme Court term is Wyeth v. Levine, asking whether a state law tort action challenging the labeling on a Wyeth drug is pre-empted by federal law. Now, the outcome of the case could be in question because of the recent announcement by Pfizer Inc. that it would acquire Wyeth. Chief Justice John Roberts Jr.'s ownership of Pfizer stock has prompted his recusal in previous cases. The decision in the case is likely to affect Wyeth's value, and, in turn, Pfizer's.
Should Chief Justice Recuse in Landmark 'Wyeth' Case?
February 10, 2009